1
|
Paolla Raimundo E Silva J, Raimundo E Silva JP, Silva Vasconcelos PG, Targino Campos L, de Medeiros Gomes J, Tolentino Leite Filho M, Menezes RPBD, Scotti MT, Tavares JF, Cristina Barbosa Silva A, Costa EMMDB. The potential of Acmella oleracea as a nutraceutical source for the symptomatic treatment of Burning Mouth Syndrome. Nat Prod Res 2023:1-7. [PMID: 37671677 DOI: 10.1080/14786419.2023.2253974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/07/2023]
Abstract
This study analysed the phytochemical profile of Acmella oleracea extract and the molecular interactions of its main compounds with TRPV1 and CB2, target receptors in the Burning Mouth Syndrome (BMS) pathogenesis. The phytochemical profile of A. oleracea's floral buds extract treated with activated charcoal (TCEE) was analysed by High-Performance Liquid Chromatography (HPLC) coupled to Mass Spectrometry (LC-MS). The quantification of spilanthol was analysed by HPLC coupled to a Diode-Array Detector (HPLC-DAD). The phytochemical analysis revealed the presence of nine alkylamides and phenolic compounds. The TCEE showed a significant increase in spilanthol content compared to the crude extract (CEE), going from 28.33 mg/g to 117.96 mg/g. The molecular docking indicated a behaviour of the alkylamides as partial TRPV1 agonists and CB2 agonists and, for the first time, indicates the action of these compounds in the symptomatic management of BMS.
Collapse
Affiliation(s)
| | | | | | - Letícia Targino Campos
- Postgraduate Programme in Dentistry, State University of Paraiba, Campina Grande, Brazil
| | - Juliana de Medeiros Gomes
- Postgraduate Programme in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, Brazil
| | | | | | - Marcus Tullius Scotti
- Postgraduate Programme in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, Brazil
| | - Josean Fechine Tavares
- Postgraduate Programme in Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa, Brazil
| | | | | |
Collapse
|
2
|
Harada Ribeiro M, Belli KC, Piccaro P, Padilla LT, Silva ACB, Santiago R, De Paula JET, Ribeiro EE, Franken M, Quadros AS, Campos CM. P4598Clinical implications and predictors of coronary perforations during chronic total occlusion percutaneous coronary interventions: insights from the multicenterLatin America CTO LATAM registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Chronic total occlusions are still considered one of the most challenging procedures in the field of interventional cardiology and the most feared complication are the perforations. In past studies and series from Asia, Europe and United States the rate of perforations in percutaneous coronary interventions are described as 0.2% whereas this rate increases to 3% when recanalization of a chronic total occlusion is attempted.
Purpose
Our study sought to identify the frequency, predictors and clinical implications of coronary perforations in chronic total occlusion percutaneous interventions in a contemporary registry with data from Latin America.
Methods
We reported the data of a prospective multi center Latin American registry from January to December 2018 in 1066 patients who underwent chronic total occlusion percutaneous interventions in 30 centers in the following countries: Brazil, Argentina, Puerto Rico, Chile, Colombia, Ecuador and Mexico. Coronary perforation was defined as evidence of extravasation dye or blood from the coronary artery during or following the procedure. A stepwise logistic regression was performed to investigate the independent predictors of coronary perforations.
Results
The mean age was 64.2±10.7 years, 79.8% were male, 35.3% diabetics and 6.7% had heart failure. The most commonly involved CTO vessel was right coronary artery (41.4%), the mean J-CTO score was 2.0±1.3 and the mean CL score was 2.7±1.6. The overall procedural success rate was 81.9%. Coronary perforation occurred in 3.3% of cases: type 1 in 1.8%, Type 2 in 0.9% and Type 3 in 0.6%. In comparison with patients without coronary perforation was observed, those with such complication required more often blood transfusion (8.6% vs. 0.7%; p<0.001), experienced more cardiac tamponade (13.4% vs. 0.4%; p<0.001), but not all-cause in-hospital mortality (0 vs. 1.0%; p=1.0; respectively). At multivariate analysis, the independent predictor of coronary perforation was an activated clotting time (ACT) during PCI >470 seconds (OR 6.5; 95% CI 2.4 - 17.3; p<0.001), baseline heart failure (OR 4.2; 95% CI 1.2 - 14.6) and J-CTO score ≥2 (OR7.5; 95% CI 1.0–59.1).
Conclusions
Coronary perforation during percutaneous interventions in Latin America occurred in 3.3% of patients, being related with adverse events but not in-hospital all-cause mortality. Pharmacological management, high anatomical complexity and heart failure were identified as independent predictors of this still and so feared complication.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- M Harada Ribeiro
- Heart Institute of the University of Sao Paulo (InCor), Interventional Cardiology, Sao Paulo, Brazil
| | - K C Belli
- Institute of Cardiology of Rio Grande do Sul, Interventional Cardiology, Porto Alegre, Brazil
| | - P Piccaro
- Institute of Cardiology of Rio Grande do Sul, Interventional Cardiology, Porto Alegre, Brazil
| | - L T Padilla
- Instituto Cardiovascular de Buenos Aires, Interventional Cardiology, Buenos Aires, Argentina
| | - A C B Silva
- Hospital São José do Avaí, Interventional Cardiology, Rio de Janeiro, Brazil
| | - R Santiago
- Hospital Pavia Santurce, Interventional Cardiology, San Juan, United States of America
| | | | - E E Ribeiro
- Heart Institute of the University of Sao Paulo (InCor), Interventional Cardiology, Sao Paulo, Brazil
| | - M Franken
- Hospital Israelita Albert Einstein, Interventional Cardiology, Sao Paulo, Brazil
| | - A S Quadros
- Institute of Cardiology of Rio Grande do Sul, Interventional Cardiology, Porto Alegre, Brazil
| | - C M Campos
- Heart Institute of the University of Sao Paulo (InCor), Interventional Cardiology, Sao Paulo, Brazil
| |
Collapse
|
3
|
Silva DR, Sardi JDCO, Freires IA, Silva ACB, Rosalen PL. In silico approaches for screening molecular targets in Candida albicans: A proteomic insight into drug discovery and development. Eur J Pharmacol 2018; 842:64-69. [PMID: 30326213 DOI: 10.1016/j.ejphar.2018.10.016] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Revised: 09/28/2018] [Accepted: 10/12/2018] [Indexed: 12/16/2022]
Abstract
Candida species are opportunistic pathogens which can cause conditions ranging from simple mucocutaneous infections to fungemia and death in immunosuppressed and hospitalized patients. Candida albicans is considered to be the species mostly associated with fungal infections in humans and, therefore, the mostly studied yeast. This microorganism has survival and virulence factors which, allied to a decreased host immunity response, make infection more difficult to control. Today, the current limited antifungal arsenal and a dramatic increase in fungal resistance have driven the need for the synthesis of drugs with novel mechanisms of action. However, the development of a new drug from discovery to marketing takes a long time and is highly costly. The objective of this review is to show that with advances in biotechnology and biofinformatics, in silico tools such as molecular docking can optimize such a timeline and reduce costs, while contributing to the design and development of targeted drugs. Here we highlight the most promising protein targets in Candida albicans for the development of drugs with new mechanisms of action.
Collapse
Affiliation(s)
- Diego Romário Silva
- Department of Physiological Sciences, Piracicaba Dental School, State University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP CEP: 13414-018, Brazil
| | - Janaína de Cássia Orlandi Sardi
- Department of Physiological Sciences, Piracicaba Dental School, State University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP CEP: 13414-018, Brazil
| | - Irlan Almeida Freires
- Department of Oral Biology, College of Dentistry, University of Florida, 1395 Center Dr., 32610 Gainesville, FL, USA
| | - Andréa Cristina Barbosa Silva
- Department of Dentistry, State University of Paraíba, Av. Cel. Pedro Targino - Centro, Araruna, PB CEP: 58233-000, Brazil
| | - Pedro Luiz Rosalen
- Department of Physiological Sciences, Piracicaba Dental School, State University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP CEP: 13414-018, Brazil.
| |
Collapse
|